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Surgicalresectionwasperformedona47-year-oldwomanforaretroperitonealmassthatweighed8.5kg.Histologicalexamination
revealed a myxoid sarcomatous tumor. Because diagnosis could not be determined by immunohistochemistry, attention was
focused on MDM2 (murine double minute) gene ampliﬁcation by ﬂuorescence in situ hybridization (FISH) analysis. The tumor
was ﬁnally determined to be a dediﬀerentiated liposarcoma. We experienced a case of a giant retroperitoneal dediﬀerentiated
liposarcoma. FISH analysis was useful for the diagnosis and determination of the therapeutic strategy.
1.Introduction
Liposarcoma is the most common of the soft tissue sarcomas
encountered in adulthood [1]. Liposarcomas are generally
found in the extremities, retroperitoneum, and in inguinal
lesions. The clinical characteristics of liposarcomas closely
reﬂect their pleomorphic histologies, and the large size
lesions are more common in the retroperitoneum [2, 3].
Herein, we report a case of a dediﬀerentiated liposarcoma
that weighed 8.5kg for which FISH analysis contributed to
the diagnosis.
2.CaseReport
A 47-year-old woman was admitted to the Nagoya City Uni-
versity Hospital, Nagoya, Japan, complaining of an abdom-
inal swelling that had been present for the past 12 months.
Her abdomen was markedly swollen and felt hard without
tenderness. Peripheral blood examination revealed slight
anemia and slight elevation of C-reactive protein. No other
disorders, including any tumor markers, were detected. A
computed tomography scan (CT) showed two masses in
the retroperitoneum, one of which was 26 ×15 ×29cm
and enhanced slightly, and the right kidney was involved
and pushed aside. Almost all retroperitoneal cavities were
ﬁlled with the giant tumor. The other mass was walnut-
sized tumor adjacent to the large one, and mostly of low
density. Magnetic resonance imaging (MRI) revealed the
giant tumor was T1-low intensity and T2-high intensity,
but the small tumor was T1-high intensity, with a changed
low signal in fat suppression (Figure 1). This indicated
that the small tumor was mainly fat-containing, and the
giant tumor appeared to be mainly composed of mucinous
tissue. Under general anesthesia, the tumor was excised
with the right kidney en bloc. There was not much
adhesion to surrounding tissues. Upon gross examination,
the tumor was well circumscribed and encapsulated and
weighed 8.5kg (Figure 2). The tumor had two components
as determined by CT and MRI. The two components were
very clearly divided. The small one was yellowish, and
histopathologically, they were mainly composed of fat cells
that varied in size, that is, mature-appearing adipose tissue2 ISRN Urology
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Figure 1: (a) shows T1-weighted images, (b) shows T2-weighted images, and (c) shows T1-weighted and fat suppression images on MRI.
The giant tumor was T1 low intensity and T2 high intensity, but the small tumor was T1 high intensity, and with a changed low signal in fat
suppression (long arrow). The right kidney was involved and pushed aside (small arrow).
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Figure 2: (a) shows resected mass and (b) shows two component of tumor as determined by CT and MRI after ﬁxation. Macroscopically,
the resected mass weight was 8.5kg. The giant tumor was white, and the small one was yellowish (arrow: right kidney).
with scattered lipoblasts exhibiting large hyperchromatic
nuclei. Immunohistochemical analysis revealed that the cells
were strongly stained by S-100 protein which is a marker
for fat (Figure 3). Therefore, this small tumor was diagnosed
as a well-diﬀerentiated liposarcoma. On the other hand,
giant tumor was white and, histopathologically, mainly
contained abundant mucinous mesenchyme and ﬁlled with
atypical spindle cells. There was extensive in-depth invasion
into the renal parenchyma, but the surgical margin was
negative. According to immunohistochemical analysis, the
poorlydiﬀerentiatedtumorcellshadnoexpressionofseveral
mesenchymalmarkerscontainingS-100protein.Therefore,a
comorbid malignant ﬁbrous histiocytoma (MFH), or other
myxoid tumor could not be ruled out. Consequently, we
focused attention on FISH analysis, using speciﬁc probes
for the MDM2 gene (Figure 3). The ampliﬁcation of MDM2
gene was detected in the nuclei of both small and giant
tumors. Thus, a deﬁnitive diagnosis was made of the two
tumors as a dediﬀerentiated liposarcoma. The patient was
strictly observed without adjuvant therapy. During the last
follow-up investigation, performed 12 months after surgical
intervention, the patientbecame well with no clinical or
radiological signs of recurrence.
3. Discussion
Liposarcomas are histologically deﬁned as tumors com-
posed of lipoblasts. They are currently classiﬁed into ﬁve
groups: myxoid liposarcomas, well-diﬀerentiated liposarco-
mas, round cell liposarcomas, pleomorphic liposarcomas,ISRN Urology 3
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Figure 3: (a)–(c) show the high-power-magniﬁcation microscopic specimen of the small tumor, and (d)–(f) show those of the giant tumor.
The two tumors had diﬀerent expressions of S-100 protein (b), (e), but many MDM2 red signals were recognized in nuclei of both tumors
(c), (f) (Green: chromosome 12).
and dediﬀerentiated liposarcomas. Dediﬀerentiated liposar-
comas are characterized by the coexistence of well-diﬀer-
entiated and poorly diﬀerentiated, nonlipogenic areas in a
portion of the same tumor or in the primary tumor and
the recurrent tumor [4]. However, in this case, the two
tumors were clearly divided and expression of S-100 protein
was not detected in the poorly diﬀerentiated component.
Therefore, we could not rule out the coexistence of a
well-diﬀerentiated liposarcoma and MFH. Dediﬀerentiated
liposarcomas have been a challenge to distinguish from other
high-grade sarcomas, and some reports have described that
most of MFH developing in the retroperitoneum are dedif-
ferentiated liposarcomas [5, 6]. Recently, well-diﬀerentiated
liposarcoma/atypical lipomatous tumors and dediﬀerenti-
atedliposarcomashavebeenshownbycytogeneticstoharbor
ring and giant marker chromosomes consisting of ampli-
cons of the 12q13–15 region, resulting in ampliﬁcation
of several genes, including most notably MDM2 [7]. In
addition, the prognosis of lipomatous tumors has been
recently clariﬁed on the basis of the genetic background
[8]. There is little precise information as to the eﬀectiveness
of various therapies, but radical excision is the treatment
of choice for liposarcomas, especially in dediﬀerentiated
liposarcomas expressing the MDM2 gene [3]. Some reports
described postoperative radiation as a valuable adjuvant to
surgical therapy, especially for the myxoid type, but the
eﬃcacy remains to be established [9]. Few reports have
described the eﬀectiveness of adjuvant chemotherapy. To our
knowledge, this case represents the second largest primary
retroperitoneal dediﬀerentiated liposarcoma that has been
reported in the English literature [10]. Complementary
molecular testing may reﬁne the therapeutic strategy and
result in avoiding ineﬀective adjuvant therapy.
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